Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.68 +0.14 (+0.57%)
Streaming Delayed Price Updated: 11:17 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Which Is The Healthiest Investment: Merck Or Pfizer
Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
Looking At Pfizer's Recent Unusual Options Activity
Via Benzinga
32-Year-Old Investor With Massive NVDA Gains And $350K Cash Asks Reddit: 'What's Stopping Me From Putting It All In SCHD?'
Investors are often driven by the pursuit of massive gains and few assets capture this ambition better than individual stocks–like Nvidia Corporation (NASDAQ: 
Via Benzinga
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
Via The Motley Fool
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Via The Motley Fool
1 Reliable Dividend Stock You Can Buy Now and Hold at Least a Decade
Via The Motley Fool
Curious about the most active S&P500 stocks in today's session?
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
Pfizer Offloads Its Last 7% Stake In Consumer Health Haleon For Over $3 Billion
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%. 
Via Benzinga
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the... 
Via Benzinga
Topics Government
Exposures Political
3 Dividend Stocks to Buy for Reliable Passive Income
Via The Motley Fool
4 Analysts Assess Pfizer: What You Need To Know
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. 
Via Benzinga
3 Value Stocks in the Doghouse
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
The Smartest Dividend Stocks to Buy With $150 Right Now
Via The Motley Fool
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (UPDATED)
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased costs in federal health programs. 
Via Benzinga
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
Via The Motley Fool
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies. 
Via Benzinga
10 Highest Yielding Blue Chip Stocks Now
Blue-chip stocks are established, financially strong, and consistently profitable publicly traded companies. 
Via Talk Markets
Topics Stocks / Equities
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients. 
Via Benzinga
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
The companies are looking to use protein degradation to take on some forms of breast cancer. 
Via Investor's Business Daily
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
From Arvinas Inc.
Via GlobeNewswire
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits
Elizabeth Warren Raises Questions On Robert F Kennedy's Mar-A-Lago Dinners With Big Pharma: American People Deserve To Know About The Deals Made
Sen. Elizabeth Warren and other lawmakers raised concerns about Robert F. Kennedy Jr.'s private dinners with pharmaceutical executives at Mar-a-Lago, questioning his commitment to reducing corporate... 
Via Benzinga
The State of Weight Loss Drugs
Via The Motley Fool
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025. 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS